Highly cell permeable purine compound that acts as a selective and ATP-competitive inhibitor of CDKs (IC50=6.6µM, 0.41µM, 5.5µM, 15µM and 3.9µM for CDK1/cyclin B, CDK2/cyclin A, CDK4/cyclin D, CDK5/p25 and CDK7/cyclin H) and displays anticancer properties. Causes cell cycle arrest at the G2/M phase and induces apoptosis by activating caspases and downregulating survivin.
Product Details
| Alternative Name: | 4-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide |
| |
| Formula: | C23H30N6O2 |
| |
| MW: | 422.5 |
| |
| CAS: | 444723-13-1 |
| |
| Purity: | ≥95% (HPLC) |
| |
| Identity: | Determined by 1H-NMR and MS. |
| |
| Appearance: | White to off-white solid. |
| |
| Solubility: | Soluble in DMSO (10mg/ml). |
| |
| Shipping: | Ambient |
| |
| Long Term Storage: | +4°C |
| |
| Use/Stability: | Stock solutions are stable for up to 6 months when stored at -20°C. |
| |
| Handling: | Protect from light. Packaged under inert gas. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation: M. Pennati, et al.; Mol. Cancer Ther.
4, 1328 (2005),
Abstract;
